XenoSTART is an industry-leading oncology translational research organization focused on the development and utilization of PDX models. Founded in 2007, XenoSTART was created in close collaboration with The START Center, an international cancer treatment and research organization. This partnership provides the unique ability to generate clinically-relevant XenoSTART patient-derived xenograft (XPDX) models.
Our diverse repository of XPDX (XenoSTART PDX) models are clinically annotated and include patient treatment history and outcome. The models are characterized through genomic profiling, histologic analysis, next generation sequencing, and in vivo drug sensitivity to relevant standards of care.
Our models can accelerate preclinical discovery and drug development through the following turn-key services:
In vivo PK/PD and efficacy studies
In-licensing of models for proprietary studies
Orthotopic and radiotherapy studies [collaboration with our partners]
Ex vivo and organoid studies [collaboration with our partners]
In vivo efficacy panel screens [indication or target focused]
Cell line development
Custom model development
Company Details
- Employees
- 24
- Address
- San Antonio, Tx 78229, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- In vivo PK/PD and efficacy studies.
- HQ
- San Antonio, TX
Xenostart Questions
Xenostart's website is https://portal.xenostart.com/login
Xenostart's LinkedIn profile is https://www.linkedin.com/company/xenostart
Xenostart has
24 employees.
View email and phone details for 24
employees at Xenostart.
Xenostart's industry is
Biotechnology Research
Xenostart's categories are Biotechnology Research
